However, Aβ-reducing therapies alone are not able to hinder the progression of tau-mediated neurodegeneration in patients with AD [7], underlining that different therapeutical approaches are needed and that many aspects of AD etiopathogenesis are still obscure. This evidence concerns the gene MAPT and Alzheimer disease.